Samjin Pharmaceuticals Co., Ltd. (005500.KS) Stock
Samjin Pharmaceuticals Co., Ltd.

Company profile
Samjin Pharmaceuticals reported revenue of 309.13 billion KRW for fiscal year 2025, up 0.3% from fiscal year 2024, and net income of 24.17 billion KRW. That is a net profit margin of 7.8% for fiscal year 2025. In Q1 2026 (the quarter ended March 31, 2026) revenue was 68.07 billion KRW, down 3.9% from a year before. South Korea was its largest region in fiscal year 2022, with 98% of revenue. In Q1 2026 it reported net income of 1.39 billion KRW, against net income of 3.72 billion KRW a year earlier. Our analysis of its filings shows revenue growing from 292.13 billion KRW in fiscal year 2023 to 309.13 billion KRW in fiscal year 2025, 2.9% a year on average.
What stands out
- Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Samjin Pharmaceuticals Co., Ltd.
Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also develops SA001, which is in Phase II clinical trial for the treatment for dry eye syndrome and Sjogren syndrome; SJP1804 medicine that is Phase I clinical trial to treat macular degeneration; and SJP1604, which is in Phase I clinical trial for cancer; SJP1901 and SJP1902 for cancer treatment; SJP 1801 to treat Alzheimer's and Parkinson's disease; SJP006, an anti-viral product; and SJP003 for treatment of diabetes. In addition, the company's preclinical product is SJP1602 for the treatment of cancer. Samjin Pharmaceuticals Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.
Largest shareholders
- Samjin Pharmaceuticals Co., Ltd.12.33%
- ARIBIO Co., Ltd.8.34%
- Eui-Hwan Cho4.274 %4.27%
- Gyu-Seok Cho4.204 %4.20%
- Gyu-Hyung Cho4.204 %4.20%
Share of the company, as of September 25, 2026
Leadership
- Kyu Seok Cho — President, CEO & Chairman, 54
- Ji-hyeon Choi — President, CEO & Director, 51
- Kyu Hyung Cho — VP, Internal Director & Head of Sales, 50
- Jee Sun Choi — VP & Internal Director, 48
- Kim Jung-il — Production Head, 64
How much revenue does Samjin Pharmaceuticals make?
Samjin Pharmaceuticals reported 309.13 billion KRW in revenue for fiscal year 2025, up 0.3% from 308.35 billion KRW in fiscal year 2024. In Q1 2026 revenue was 68.07 billion KRW.
Where does Samjin Pharmaceuticals make most of its revenue?
South Korea: 98% of revenue by region in fiscal year 2022, followed by Overseas (2%).
What companies are similar to Samjin Pharmaceuticals?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include HLB Pharmaceutical Co., Ltd. (047920.KQ), Inventage Lab, Inc. (389470.KQ), JW Holdings Corporation (096760.KS), Korea United Pharm Inc. (033270.KS).
How has Samjin Pharmaceuticals' revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 250.07 billion KRW; FY2022, 274.03 billion KRW; FY2023, 292.13 billion KRW; FY2024, 308.35 billion KRW; FY2025, 309.13 billion KRW.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Samjin Pharmaceuticals Co., Ltd. (005500.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/005500.KS